Short Interest Update on Radius Health (RDUS)

Radius Health (RDUS) : The bears are holding on to their shorts in Accenture Plc with 4 more days remaining for them to cover their positions. The bearish positions have increased from 6,199,226 on Jul 29, 2016, to 6,506,154, on August 15, 2016. Daily, 1,597,170 shares are traded, which shows the high interest of the traders in the stock. The net addition of short open interest is 306,928 shares, which is an increase of just 5%. The total short interest of 18.2% of the float indicates that there arent many bears on this stock at the current prices. The short interest information was released on Wednesday Aug 24th after the market close.

Radius Health (NASDAQ:RDUS): The stock opened at $55.96 on Wednesday but the bulls could not build on the opening and the stock topped out at $57.59 for the day. The stock traded down to $54.00 during the day, due to lack of any buying support eventually closed down at $54.65 with a loss of -3.68% for the day. The stock had closed at $56.74 on the previous day. The total traded volume was 1,219,941 shares.


Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.